A 41-site clinical trial, testing the restorative effect that adult bone marrow stem cells have on damaged or injured myocardium in heart attack patients, is being led at Wake Forest Baptist by Sanjay Gandhi, MD.
Phase I of the research study found that stem cells derived from bone marrow (mesenchymal stem cells) were safe for patients and may have the ability to limit scar formation, improve heart function and preserve tissue following a first heart attack.
Phase I was a multicenter study of 53 patients which demonstrated that the treatment was safe in adults, and those patients given this
Two scientists at the Fred Hutchinson Cancer Research Center in Seattle have been awarded $16.7 million for stem cell research projects.
Dr. Irwin Bernstein and Beverly Torok-Storb received the federal funding from the National Heart, Lung and Blood Institute. Their award is part of a $170 million effort divided among 18 scientific teams.
Torok-Storb will work with Dr. Mortimer Poncz of Children’s Hospital of Philadelphia to develop molecular and cell-based therapies for a range of blood diseases, using an $8.2 million grant.
Bernstein will work with Edward Morrisey of the University of Pennsylvania to study how biochemical reactions inside cells affect cell
Children born with so-called “bubble boy” disease have the best chance of survival if they undergo a hematopoietic stem cell transplant as soon after birth as possible, according to a detailed analysis of 10 years of outcome data by researchers at the Harvard-affiliated Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
Researchers say the findings support expanding newborn screening for severe combined immune deficiency (SCID), a disorder that leaves affected infants so vulnerable to infection that most die within the first year of life if untreated.
The study, published today in the New England Journal of Medicine, analyzed data on 240 children
Scientists and transplant clinicians at the Ansary Stem Cell Institute at Weill Cornell Medical College and the Center for Cell Engineering at Memorial Sloan Kettering Cancer Center have been awarded a $15.7 million, four-year research grant from the New York State Stem Cell Science Program (NYSTEM).
The scientists will translate their approach to manipulate hematopoietic stem cells to cure acquired and inherited blood disorders. For many patients with such blood diseases, including sickle cell disease, the only hope for a cure requires transplanting normal blood stem cells.
But in many instances suitable blood stem cells cannot be found or there are
Cancer patients in remission at a Suffolk hospital can have their own cells transplanted back to them with the use of a new piece of equipment.
The stem-cell bath defrosts frozen cells taken from people recovering from blood cancers myeloma, leukaemia and lymphoma at Ipswich Hospital.
When transplanted back to the patient following treatment the cells can help their body create new bone marrow.
The bath cuts down on the need for patients to travel to other hospitals.
The stem cells are stored at -190C in liquid nitrogen and can be kept for several years at the national blood transfusion centre in Cambridge.